文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肝硬化患者的低密度脂蛋白胆固醇与临床结局:一项全国性队列研究。

Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study.

作者信息

Kim Byung Sik, Kim Jiyeong, Choi Nayeon, Kim Hyun-Jin, Shin Jeong-Hun

机构信息

Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea.

Biostatistics Lab, Medical Research Collaborating Center, Industry-University Cooperation Foundation, Hanyang University, Seoul, Republic of Korea.

出版信息

Ann Med. 2025 Dec;57(1):2551813. doi: 10.1080/07853890.2025.2551813. Epub 2025 Aug 30.


DOI:10.1080/07853890.2025.2551813
PMID:40884310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12404081/
Abstract

BACKGROUND: The association between low-density lipoprotein cholesterol (LDL-C) levels and clinical outcomes in patients with liver cirrhosis (LC) remains unclear. In this study, we aimed to investigate the association between LDL-C levels and cardiovascular events, along with all-cause death in patients with LC, using a nationwide database. MATERIALS AND METHODS: This retrospective cohort study included 303,988 patients with LC identified from the Korean National Health Insurance Service database who underwent health examinations between 2009 and 2017. Patients were categorised into six LDL-C groups (<70, 70-99, 100-129, 130-159, 160-189, and ≥190 mg/dL). The primary outcomes were (1) a composite of myocardial infarction and ischaemic stroke and (2) all-cause death. RESULTS: Higher LDL-C levels were associated with a dose-dependent increase in the risk of cardiovascular events. Compared to the reference group (<70 mg/dL), patients with LDL- ≥ 190 mg/dL had a 1.77-fold higher risk of a composite outcome and a 2.96-fold increased risk of myocardial infarction. Conversely, a U-shaped relationship was observed between LDL-C levels and all-cause death, with the lowest risk observed in the 130-159 mg/dL group. These findings were consistent across the subgroups with compensated or decompensated LC and various underlying aetiologies. CONCLUSION: This large-scale nationwide study demonstrated that elevated LDL-C levels are significantly associated with an increased risk of cardiovascular events in patients with LC, while both low and high LDL-C levels are associated with a higher risk of all-cause death. These findings highlight the need for individualised lipid management strategies in this high-risk population.

摘要

背景:肝硬化(LC)患者的低密度脂蛋白胆固醇(LDL-C)水平与临床结局之间的关联仍不明确。在本研究中,我们旨在利用全国性数据库调查LC患者的LDL-C水平与心血管事件以及全因死亡之间的关联。 材料与方法:这项回顾性队列研究纳入了2009年至2017年间从韩国国民健康保险服务数据库中识别出的303,988例接受健康检查的LC患者。患者被分为六个LDL-C组(<70、70 - 99、100 - 129、130 - 159、160 - 189和≥190mg/dL)。主要结局为:(1)心肌梗死和缺血性卒中的复合结局;(2)全因死亡。 结果:较高的LDL-C水平与心血管事件风险呈剂量依赖性增加相关。与参照组(<70mg/dL)相比,LDL-C≥190mg/dL的患者复合结局风险高1.77倍,心肌梗死风险增加2.96倍。相反,LDL-C水平与全因死亡之间呈U形关系,130 - 159mg/dL组的风险最低。这些发现在代偿期或失代偿期LC以及各种潜在病因的亚组中均一致。 结论:这项大规模的全国性研究表明,LC患者LDL-C水平升高与心血管事件风险增加显著相关,而LDL-C水平过低和过高均与全因死亡风险较高相关。这些发现凸显了在这一高危人群中制定个体化血脂管理策略的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/bd7af8d24edb/IANN_A_2551813_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/3561cde30368/IANN_A_2551813_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/23462aacf1b3/IANN_A_2551813_F0002a_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/d1079c018da3/IANN_A_2551813_F0002b_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/bd7af8d24edb/IANN_A_2551813_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/3561cde30368/IANN_A_2551813_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/23462aacf1b3/IANN_A_2551813_F0002a_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/d1079c018da3/IANN_A_2551813_F0002b_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a04/12404081/bd7af8d24edb/IANN_A_2551813_F0003_C.jpg

相似文献

[1]
Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study.

Ann Med. 2025-12

[2]
Associations Between Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Outcomes in Patients Undergoing Dialysis: A Nationwide Cohort Study.

J Clin Med. 2025-7-8

[3]
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.

Cochrane Database Syst Rev. 2023-5-31

[4]
Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction.

J Am Heart Assoc. 2022-9-6

[5]
Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort.

Ann Med. 2025-12

[6]
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.

Cochrane Database Syst Rev. 2025-5-6

[7]
Assessing the impact of aggressive versus intermediate LDL-C goal achievement in Asian adults: a retrospective cohort study using national health insurance service-senior cohort.

Lipids Health Dis. 2025-8-8

[8]
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.

Circulation. 2017-9-6

[9]
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.

Circulation. 2025-1-28

[10]
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.

BMJ. 2022-5-4

本文引用的文献

[1]
Risk of Coronary Artery Disease in Patients with Liver Cirrhosis: A Systematic Review and Meta-analysis.

J Clin Transl Hepatol. 2025-2-28

[2]
Clinical Implications of Inflammation in Patients With Cirrhosis.

Am J Gastroenterol. 2025-1-1

[3]
Low-Density Lipoprotein Cholesterol, Cardiovascular Disease Risk, and Mortality in China.

JAMA Netw Open. 2024-7-1

[4]
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

J Hepatol. 2024-9

[5]
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.

Am J Prev Cardiol. 2024-3-18

[6]
J-shaped association between LDL cholesterol and cardiovascular events: A longitudinal primary prevention cohort of over 2.4 million people nationwide.

J Adv Res. 2024-4

[7]
The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health.

J Am Coll Cardiol. 2022-12-20

[8]
Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury.

Life (Basel). 2022-7-12

[9]
Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research.

J Lipid Atheroscler. 2022-5

[10]
Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions.

Gastroenterology Res. 2022-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索